Searched for
INTAS
India raises price cap on cancer drugs to tackle shortageIndia's drug price regulator has increased the ceiling prices of cancer drugs cisplatin and carboplatin by 50% to tackle shortages caused b...- Indian cancer patients battle shortage of key drugs as platinum costs surgeCancer patients in India are struggling to find essential platinum-based drugs. A surge in global platinum prices and supply chain issues a...
- Delhi HC allows Intas to sell cancer drug Bevatas, sets aside order favouring Sun PharmaThe Delhi High Court division bench has ruled in favor of Intas Pharmaceuticals, allowing the company to introduce its anti-cancer medicati...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Intas Pharma completes acquisition of UDENYCA biosimilar for $558 millionIntas Pharma finalized its acquisition of UDENYCA, a biosimilar to Neulasta, from Coherus Life Sciences for $558 million in December 2024. ...
- Biosimilar brand buy to help Intas Pharma take on biggiesIn one of the biggest deals worldwide for a biosimilar brand, Ahmedabad-based Intas agreed to buy Udenyca-the brand name for medication peg...
- Intas low-balls Mallinckrodt unit bid to $1bn on legal fearsLast year, media reports mentioned that Intas had emerged as a strong contender to acquire Mallinckrodt unit in a deal estimated between $1...
- ChrysCapital sells 3% in Intas to Capital InternationalChrysCapital will continue to hold a 3% stake in Intas, making it the longest and probably the most successful private equity investment in...
- Intas buys Teva's UK & Ireland assets for $764 million to break into global top 20 generic players clubWith the acquisition of Teva’s products, sold through erstwhile Actavis’ operations, Intas is set to emerge as a top player in the UK gener...
- Intas Pharmaceuticals to launch its first biosimilar in US in 9-12 monthsIntas is the only domestic firm with two biosimilars filed for registration in the US and it looks to deliver affordable and innovative pha...
- Delhi High Court comes to Intas rescue, stops Arinna Lifescience for trademark violationDelhi High Court gave relief to Ahmedabad-based drug maker, Intas Pharmaceuticals, by granting an ex-parte injunction against the sale of V...
- CCI clears Temasek's 10.16% stake buy in Intas PharmaceuticalsTemasek Holding's proposed 10.16% stake purchase in Indian firm Intas Pharmaceuticals has got the approval of the Competition Commission.
- Temasek, two other PEs eye ChrysCapital’s 10 pc stake in Intas PharmaThree private equity funds are in independent talks to purchase rival ChrysCap’s stake Intas Pharmaceuticals for about $150 million or Rs 9...
- Intas settles patent litigation with Hoffmann-La Roche for capecitabine tabletAhmedabad-based drug maker, Intas Pharmaceuticals Ltd and its US-based wholly owned subsidiary Accord Healthcare Inc. has entered into a se...
- Intas ex-employee objects to amalgamation planAn affidavit of objection challenging Intas' amalgamation was filed by Mani Iyer, a former executive director of Intas Biopharmaceuticals, ...
- ChrysCapital, Blackstone and Advent Capital in race to buy stake in Intas Pharma for Rs 250 crore3 PE firms are vying for a minority stake in generic drugmaker Intas Pharmaceuticals, two people familiar with the development told ET.
- Intas gets SEBI nod for IPO for raising Rs 800 croreIntas Pharmaceuticals has received SEBI clearance for its IPO. The issue was expected to hit the market in May, but Intas is still undecide...
- Intas Biopharma in talks with Japanese co for outlicensingIntas Biopharmaceutical Ltd, a group company of the Rs 1,600-crore Intas Pharmaceuticals Ltd, would soon enter into an out-licensing and su...
- Intas Pharma IPO to raise Rs 800 cr, fund acquisitionsIntas Pharma plans to raise Rs 750-800 cr through IPO that will help it raise fresh funds for acquisitions besides allowing PE investor Chr...
- Mauritius-based FIIs to pick up 47% in Intas' biotech armA clutch of investors are set to pick up 47% stake in the Intas Biopharmaceuticals, the biotech arm of Ahmedabad-based pharma major Intas P...
Load More
